

Conference on ‘Over- and undernutrition: challenges and approaches’

Symposium 1: Overnutrition: consequences and solutions Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome

J. Bernadette Moore

Nutritional Sciences Division, Faculty of Health and Medical Sciences, University of Surrey, Guildford,
Surrey GU2 7XH, UK

Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease in both adults and children worldwide. As a disease spectrum, NAFLD may progress from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. An estimated 20–35% of the general population has steatosis, 10% of whom will develop the more progressive non-alcoholic steatohepatitis associated with markedly increased risk of cardiovascular- and liver-related mortality. Development of NAFLD is strongly linked to components of the metabolic syndrome including obesity, insulin resistance, dyslipidaemia and type 2 diabetes. The recognition that NAFLD is an independent risk factor for CVD is a major public health concern. There is a great need for a sensitive non-invasive test for the early detection and assessment of the stage of NAFLD that could also be used to monitor response to treatment. The cellular and molecular aetiology of NAFLD is multi-factorial; genetic polymorphisms influencing NAFLD have been identified and nutrition is a modifiable environmental factor influencing NAFLD progression. Weight loss through diet and exercise is the primary recommendation in the clinical management of NAFLD. The application of systems biology to the identification of NAFLD biomarkers and factors involved in NAFLD progression is an area of promising research.

Non-alcoholic fatty liver disease: Metabolic syndrome: Systems biology

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is the pathological accumulation of fat in the liver in the absence of alcohol intake. Described initially only 30 years ago^(1,2), it is now the leading cause of liver disease in developed countries, with an estimated prevalence of 20–35% in the general population. The occurrence of NAFLD is strongly linked to obesity, insulin resistance and other components of the metabolic syndrome. From a nutrition and public health perspective the two major concerns are the rising incidence of NAFLD in children and the convincing evidence that NAFLD is an independent risk factor for CVD.

The term NAFLD encompasses a spectrum of histologically-defined liver disorders. Disease can progress from macrovesicular lipid accumulation in the hepatocytes

(termed steatosis) to non-alcoholic steatohepatitis (NASH; steatosis in the presence of inflammatory infiltrate possibly with some fibrosis) to outright fibrosis, cirrhosis and even hepatocellular carcinoma. A combination of environmental and genetic factors determines individual risk of NAFLD development and progression, with a clear role for nutrition as a modifiable environmental risk factor. Pathogenesis of NAFLD was initially envisaged as a ‘two-hit process’⁽³⁾ with fat accumulation in hepatocytes viewed as the primary insult and increased oxidative stress leading to inflammation being the second ‘hit’ in the progression to NASH and fibrosis. However, at the cellular level mechanisms influencing disease progression are clearly multi-factorial and dependent on numerous genetic and environmental interactions. Future analysis and modelling of NAFLD progression must take account of this complexity in a systems biology fashion.

Abbreviations: ALT, alanine aminotransferase; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
Corresponding author: Dr J. Bernadette Moore, fax +44 1483 686401, email j.b.moore@surrey.ac.uk

Diagnosis

The majority of cases of NAFLD are identified after an incidental finding of either elevated liver enzymes on routine blood tests or suspected fatty liver on abdominal imaging in patients consuming little or no alcohol⁽⁴⁾. After the exclusion of substantial alcohol consumption, which is now defined as >20 g/d in men and >10 g/d in women, alternative causes of fatty liver (nutritional, genetic, viral, metabolic, drug) must also be excluded before diagnosis of NAFLD. While liver enzymes such as alanine aminotransferase (ALT) and γ -glutamyl transpeptidase levels may be found to be elevated, they are not specific to NAFLD and the full histological spectrum of NAFLD has been observed in patients with normal ALT levels⁽⁵⁾. Non-invasive imaging techniques used for diagnosis of NAFLD include ultrasound, computed tomography, MRI and proton magnetic resonance spectroscopy, each of which has its own set of advantages and disadvantages⁽⁶⁾. While all these techniques yield information about fat distribution in the liver, MRI and proton magnetic resonance spectroscopy can quantify the total amount of fat in the liver. A population study using proton magnetic resonance spectroscopy to assess liver fat has found approximately one-third of subjects with hepatic steatosis, of whom 79% have normal ALT levels⁽⁷⁾. These data highlight the concern that NAFLD prevalence as assessed by liver enzyme alterations is grossly underestimated.

Ultrasound-based transient elastography and magnetic resonance elastography are currently being investigated for their ability to assess the stage of liver fibrosis^(8,9). However, transient elastography has been shown to fail at a BMI >28 kg/m²⁽¹⁰⁾ and magnetic resonance elastography remains experimental⁽¹¹⁾. Although algorithms combining biochemical markers and patient variables have been developed for predicting steatosis⁽¹²⁾, steatohepatitis⁽¹³⁾ and fibrosis⁽¹⁴⁾ in NAFLD, they require independent population validation and still lack sensitivity and specificity for widespread use. Histological assessment of liver biopsies remains the gold standard for diagnosing and assessing the stage of NASH. However, liver biopsy is invasive and associated with morbidities⁽¹⁵⁾ and rare cases of mortality⁽¹⁶⁾, precluding its routine use in screening for NAFLD or for repeated assessment of either disease progression or response to therapy. Furthermore, as histological lesions are not evenly distributed in the liver, considerable sampling error and misdiagnosis exists⁽¹⁷⁾. Consequently, the identification and validation of non-invasive biomarkers capable of diagnosing and assessing the stage of NAFLD is a research priority⁽¹⁸⁾.

Epidemiology

The lack of an inexpensive non-invasive screening test for NAFLD means that the true population prevalence remains unknown. Evidence from autopsy^(19,20) and imaging^(7,21,22) studies demonstrates NAFLD in 20–35% of populations worldwide, with 10% of these cases being NASH. Prevalence is much higher among obese patients^(20,23–27) and patients with type 2 diabetes^(28–30), with NAFLD found in 70–80% of patients, 25–70% of whom have

advanced disease, NASH and fibrosis. There are distinct ethnic differences in the prevalence of NAFLD^(7,31). The largest multiethnic population study to date (n 2287) has found the highest frequency of NAFLD in Hispanics (45%) compared with Whites (33%) and Blacks (24%); a gender difference is only observed in Caucasians (42% men, 24% women)⁽⁷⁾.

It is of considerable concern that NAFLD is now the most common cause of liver disease in children. Incidence of paediatric NAFLD has risen sharply in the last three decades, corresponding with the worldwide increase in childhood obesity. A retrospective review of paediatric autopsy reports in the USA has found fatty liver in 13% of children and 38% of obese children between 2 and 19 years of age⁽³²⁾. Estimates of NAFLD prevalence in obese children using ultrasonography range from 45% to 60%^(33–36), although no survey has been carried out in a UK population. However, the International Obesity Task Force has concluded that the lowest estimated prevalence of hepatic steatosis is 28% among obese children in the EU⁽³⁷⁾. Of particular concern are very recent datasets showing that NAFLD in overweight and obese children is not only strongly associated with cardiovascular risk factors⁽³⁸⁾, but also with atherosclerosis as measured by carotid intima-media thickness⁽³⁹⁾. Since the rate of obesity in the UK in 2006 was reported to be 7% for boys and 10% for girls aged 5–18 years (28% and 36% respectively being overweight)⁽⁴⁰⁾, paediatric NAFLD warrants considerable clinical and research attention.

Non-alcoholic fatty liver: disease development

The pathogenesis of NAFLD begins with the accumulation of lipid in the liver. As only a minority of patients with hepatic steatosis progress to the necroinflammatory steatohepatitis and develop fibrosis, it was originally conceptualised that a second ‘hit’ is required to induce cellular events (e.g. oxidative stress) leading to inflammation, cell death and fibrosis⁽³⁾. As with all complex diseases, it is now recognised that the phenotypic expression of NAFLD depends on a myriad of genetic, behavioural and environmental interactions⁽⁴¹⁾.

While hepatic steatosis can be viewed simplistically as an imbalance between the processes of lipid accumulation and lipid disposal, the cellular and molecular regulation of hepatic metabolism is intricate and has been the subject of a recent extensive review⁽⁴²⁾. Fat in the liver is acquired from the diet via lipoproteins, by *de novo* lipogenesis or circulating NEFA, and is removed through VLDL secretion or by β -oxidation. Derangements in each of these pathways have been associated with NAFLD. Traditionally, it was considered that lipid accumulation in the liver occurs in the context of obesity and peripheral insulin resistance, with lipid coming from an elevated plasma NEFA pool caused by increased activity of hormone-sensitive lipase and increased lipolysis from engorged adipocytes. Multiple lines of evidence suggest that this explanation is likely to be too naïve; indeed, it has been postulated that systemic insulin resistance might be secondary to NAFLD⁽⁴³⁾.




Fig. 1. Progression of non-alcoholic fatty liver disease. Of the patients presenting with steatosis 47% progress to steatohepatitis and 25–50% of patients presenting with steatohepatitis develop fibrosis or cirrhosis within 8–13 years⁽⁵⁴⁾. The 10-year prognosis for patients with NAFLD-related cirrhosis is very poor with 50% requiring a liver transplant, 20% dying of a liver-related cause and 7% developing hepatocellular carcinoma⁽⁵⁶⁾. — — →, Potential for reversal.

Stable-isotope research in patients with NAFLD has shown that although 60% of the TAG in the liver comes from the peripheral NEFA pool, elevations in fasting *de novo* lipogenesis also contribute substantially⁽⁴⁴⁾. Additional work has observed both an increase in adipose lipolysis and increased VLDL-TAG secretion from the liver in patients with NAFLD⁽⁴⁵⁾. However, not only is the increase in VLDL-TAG secretion insufficient to account for the increase in hepatic TAG content in these patients, but the VLDL-TAG is derived predominantly from ‘non-systemic’ NEFA, either from *de novo* lipogenesis or lipolysis of visceral fat. This finding is interesting in the light of very recent proton magnetic resonance spectroscopy and MRI data showing that hepatic lipid content is directly correlated with visceral fat levels⁽⁴⁶⁾. The study highlights ethnic differences in the manifestations of insulin resistance; although Hispanics and African-Americans have similar frequencies of insulin resistance, African-Americans are less likely to have NAFLD, hypertriglycerolaemia and elevated visceral fat depots. These data, as well as data showing NAFLD in non-obese individuals with normal glucose and lipid levels⁽⁴⁷⁾, suggest that NAFLD can and does occur without the backdrop of insulin resistance.

Once steatosis is established multiple mechanisms contribute to lipid-induced cellular injury⁽⁴⁸⁾. Increased mitochondrial β -oxidation of NEFA leads to an increase in reactive oxygen species. Mitochondrial defects have been observed in patients with NAFLD and impairment of the respiratory chain also produces reactive oxygen species and leads to extramitochondrial NEFA oxidation in the peroxisomes and microsomes, producing further reactive oxygen species. The overall increase in oxidative stress leads to lipid peroxidation, DNA and protein damage and ultimately cell death. In addition, the aldehyde by-products of lipid peroxidation increase production of pro-inflammatory

cytokines and recruit inflammatory cells into the liver. Inflammation and the activation of hepatic stellate cells lead to collagen production and the initiation of fibrosis⁽⁴⁸⁾.

Last, the pathogenesis of NAFLD is also mediated by transcription factors such as the sterol regulatory element-binding protein-1, the carbohydrate responsive element-binding protein and the PPAR, which are reviewed elsewhere⁽⁴⁹⁾, and influenced by circulating cytokines and adipokines. The levels of all these molecules will depend on both genetic polymorphisms and the presence or absence of disease (e.g. obesity or immune), adding a further level of complexity to the pathogenesis of NAFLD. A review of clinical studies has shown low levels of the anti-inflammatory adiponectin and high levels of the pro-inflammatory resistin, TNF α and IL-6 cytokines in patients with NAFLD⁽⁵⁰⁾. Genetic polymorphisms in these cytokines have also been investigated in patients with NAFLD, as described later.

Non-alcoholic fatty liver disease: progression and associated mortality

The prognosis of patients with NAFLD depends on the histological stage of the disease. Simple steatosis may have a relatively benign course with no increased risk of mortality, whereas NASH may progress quite rapidly and is associated with markedly increased risk of mortality^(51–54). Progression in NAFLD is difficult to assess, requiring years of follow-up and repeat biopsies that are prone to sampling errors^(17,55). The longest prospective study of the natural history of NAFLD using repeat biopsies had a mean follow-up of 13.7 years and involved 129 patients⁽⁵⁴⁾. It was reported that 47% of patients presenting with steatosis progressed to NASH and 25–50% of patients presenting with NASH developed advanced fibrosis or cirrhosis in 8–13 years (Fig. 1).




Fig. 2. Genetic and environmental factors associated with non-alcoholic fatty liver disease (NAFLD) development and progression. —>, Comorbidities (obesity, insulin resistance, hyperlipidaemia and inflammation) in addition to genetic and environmental factors influence the development and progression of NAFLD. Genetic (--->) and environmental (- ->) factors also influence the development of comorbid conditions.

Although the results underscore the fact that patients with steatosis can and do develop steatohepatitis, mortality was not found to be changed in the group presenting with steatosis, whereas survival was reported to be significantly lower in patients that had presented with NASH (70% *v.* 80% in the reference population, $P = 0.01$). Patients with NAFLD-associated cirrhosis have been shown to have a very poor 10-year prognosis, with 50% needing a liver transplant, 20% dying from a liver-related cause and 7% developing hepatocellular carcinoma (Fig. 1)⁽⁵⁶⁾. It is of great concern that a very recent study on the natural history of NAFLD in children has demonstrated that paediatric NAFLD is also progressive and can result in end-stage liver disease and death⁽⁵⁷⁾. In the cohort of sixty-six children followed over a mean of 6.4 years, two children underwent liver transplantation and two children died, while observed serial biopsies showed progression in 80% of patients.

Multiple risk factors have been associated with NAFLD progression including older age^(23,24,58), BMI^(24,53,58), insulin resistance⁽⁵⁴⁾, diabetes^(59,60), metabolic syndrome⁽⁶¹⁾ and histological NASH on diagnosis^(52,54,62). A current systematic review of ten studies has examined risk factors for progression from NASH to advanced fibrosis⁽⁶³⁾. Using multivariate analysis the review has found that only age and the presence of inflammation on initial biopsy are independent predictors of progression in 221 patients over a 5.3-year follow-up. The well-documented limitations associated with systematic reviews⁽⁶⁴⁾, particularly the choice and heterogeneity of included studies in this case, may explain why obesity, BMI and diabetes were not found to be significant predictors in this analysis.

Data relating to the mortality risks associated with NAFLD are somewhat conflicting. The first population-based cohort study that examined NAFLD and mortality has determined survival among 420 patients with NAFLD, identified through imaging or biopsy, after a mean follow-up of 7.6 years⁽⁶⁵⁾. In agreement with case series from specialist clinics^(52,54,60) NAFLD was found to be associated with lower survival and increased risk of mortality from liver disease. After 10 years of follow-up (n 161) survival was reported to be 77% *v.* 87% in the

general population. Subsequently, three independent groups have analysed data from the US Third National Health and Nutrition Examination Survey for mortality risk among suspected cases of NAFLD based on elevated ALT levels^(66–68). While two groups have found NAFLD to be associated with an increase in overall mortality^(66,67), one of these two groups has found NAFLD to be associated with a very large increase in liver-associated mortality⁽⁶⁶⁾, whereas the other group has reported a striking link between NAFLD among 45–54 year olds and CVD mortality⁽⁶⁷⁾. Conversely, the third group has reported no association between elevated ALT levels and all-cause or CVD mortality but an association with liver-related mortality⁽⁶⁸⁾. The differences may be attributable to variations in study design, patient selection strategy and statistical analysis. While these studies have the advantage of very large sample sizes from a representative sample of the general population, diagnosis of NAFLD is based on elevated ALT levels, which do not differentiate between steatosis and steatohepatitis and, as previously mentioned, are likely to severely underestimate NAFLD incidence and therefore the magnitude of mortality risk. However, the data overall show NAFLD is far from a benign diagnosis.

Genetic and environmental factors associated with non-alcoholic fatty liver disease development and progression

The development of NAFLD is strongly linked to obesity and insulin resistance. However, as there are obese individuals and individuals with diabetes who do not have NAFLD, and since NAFLD can occur in normal-weight individuals with normal glucose and lipid levels⁽⁴⁷⁾, there are obviously multiple genetic and environmental factors determining NAFLD development and progression (Fig. 2).

Initial evidence for a genetic component to NAFLD comes from familial clustering studies^(69,70) and the ethnic variation in NAFLD prevalence⁽⁷⁾. Various genetic

single-nucleotide polymorphisms have been investigated in NAFLD including single-nucleotide polymorphisms in the adiponectin^(71,72), IL-6⁽⁷³⁾, TNF α ⁽⁷⁴⁾ and apoE⁽⁷⁵⁾ genes. 'Candidate gene' studies in small cohorts have yielded somewhat conflicting results in different populations. The first genome-wide association scan conducted in 2008 in a large multiethnic population targeting NAFLD has identified the patatin-like phospholipase domain-containing protein 3 (also known as adiponutrin) gene as being strongly associated with hepatic TAG content⁽⁷⁶⁾. Allelic variants of the patatin-like phospholipase domain-containing protein 3 gene have been found to be associated with high and low amounts of hepatic fat in Hispanics and African-Americans respectively, and to be correlated with the high and low prevalence of NAFLD in these populations. Remarkably, patatin-like phospholipase domain-containing protein 3 has also been independently identified in a separate population-based genome-wide scan as one of two genetic loci influencing plasma levels of ALT⁽⁷⁷⁾. Undoubtedly, as genome sequencing continues to get cheaper and faster, studies of this type will reveal more genes that are causally related to the pathogenesis of NAFLD.

Nutrition and physical activity are important environmental factors that determine risk in NAFLD. Excess food intake and lack of exercise contribute to weight gain, which has been shown to contribute to the progression of liver fibrosis in patients with NAFLD⁽⁵⁴⁾. Specific dietary factors may also play either protective or antagonistic roles in the development and progression of NAFLD. Nutrient intakes in individuals with NAFLD have been assessed in Italian⁽⁷⁸⁾, Japanese⁽⁷⁹⁾, Israeli⁽⁸⁰⁾ and US⁽⁸¹⁾ populations; no UK cohort has been assessed to date. An increased consumption of meat and soft drinks and low consumption of fish were found to be associated with NAFLD cases compared with controls. Unsurprisingly, low intakes of PUFA and high intakes of saturated fat and cholesterol were also shown to be associated with NAFLD. Data from two randomised controlled trials in patients with NAFLD have shown beneficial effects from 6 months of dietary supplementation with *n*-3 PUFA compared with dietary advice alone^(82,83). Reductions in fatty liver observed by ultrasonography as well as improvements in serum ALT and TAG levels were found to be greater in the patients supplemented with *n*-3 PUFA. In both trials the patients receiving *n*-3 PUFA were found to be more likely to have complete fatty liver regression, suggesting a beneficial therapeutic effect for *n*-3 PUFA supplementation in NAFLD. Other studies have shown higher-carbohydrate and lower-fat diets to be associated with more progressive disease^(84,85). Conversely, very recent animal data have shown that in both mice⁽⁸⁶⁾ and non-human primates⁽⁸⁷⁾ exposure to a maternal high-fat diet leads to a disturbing development and progression of NAFLD in the offspring.

In view of the role of oxidative stress in NAFLD pathogenesis several studies have examined antioxidant supplementation as a therapeutic intervention. A recent Cochrane review of six very small and extremely diverse clinical trials has found no evidence either to recommend or advise against the use of antioxidant supplements in patients with NAFLD⁽⁸⁸⁾. However, data from pilot

studies^(89,90) and one double-blind randomised placebo-controlled trial⁽⁹¹⁾ have shown sufficient positive effects of vitamin E supplementation in patients with NAFLD for further investigation in two ongoing multicentre trials. The Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Non-alcoholic Steatohepatitis Trial⁽⁹²⁾ in adults and the Treatment of Non-alcoholic Fatty Liver Disease in Children Trial⁽⁹³⁾ both involve 96 weeks of treatment and will measure improvements in histology as well as ALT levels. While the former trial has three arms and includes a placebo group, the latter trial in children will compare metformin treatment with vitamin E supplementation. Data from these trials, whether negative or positive, should end the debate on the potential efficacy of vitamin E supplementation in NAFLD.

Small intestinal bacterial overgrowth may be an additional environmental factor involved in NAFLD pathogenesis, and dietary supplements such as probiotics could have a beneficial effect. Evidence from animal studies shows that small intestinal bacterial overgrowth increases gut permeability leading to portal endotoxaemia and increased circulating inflammatory cytokines, both of which have been implicated in the progression of NAFLD⁽⁹⁴⁾. Several studies have reported an association between small intestinal bacterial overgrowth and the progression of NAFLD⁽⁹⁵⁻⁹⁷⁾ and in one small human study treatment with antibiotics has been shown to result in an increase in fasting insulin levels⁽⁹⁷⁾. Limited evidence from animal models and one preliminary human study suggest that supplementation with the probiotic VSL#3[®] (a combination of nine strains of various bifidobacteria, lactobacillus and *Streptococcus thermophilus*; VSL Pharmaceuticals, Inc., Gaithersburg, MD, USA) may possibly be beneficial in NAFLD, but data are mixed⁽⁹⁸⁻¹⁰⁰⁾. More research in this area is warranted.

Non-alcoholic fatty liver disease, the metabolic syndrome and CVD risk

The metabolic syndrome was originally defined as a cluster of CVD risk factors with insulin resistance as the underlying pathogenic factor⁽¹⁰¹⁾. The third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) defines metabolic syndrome as being any three or more of five variables: increased waist circumference; hypertriglycerolaemia; hypertension; low HDL-cholesterol; hyperglycaemia⁽¹⁰²⁾. Metabolic syndrome is highly prevalent among patients with NAFLD in multiple populations and is strongly associated with progressive disease^(61,103-105). Furthermore, a Japanese prospective study (*n* 3147) has demonstrated that patients with metabolic syndrome, as defined by Adult Treatment Panel III⁽¹⁰²⁾, are four to eleven times (men and women respectively) more likely to have developed NAFLD on follow-up⁽¹⁰⁶⁾. Likewise, children with metabolic syndrome, as defined by Adult Treatment Panel III⁽¹⁰²⁾, have been shown to be five times more likely to have NAFLD⁽³⁸⁾. This strong relationship between NAFLD and the metabolic syndrome has led to the

description of NAFLD as the hepatic component of the metabolic syndrome.

Indeed, in the last 5 years NAFLD has emerged as an independent risk factor for CVD. Several studies have observed increased carotid intima-media thickness and carotid plaques in patients with NAFLD, including children^(39,107–111). Although there has been some conflicting work⁽¹¹²⁾, a systematic review has found that carotid plaques are two to three times more likely to be observed in patients with NAFLD and intima-media thickness is strongly associated with NAFLD⁽¹¹³⁾. Furthermore, multiple population studies have observed increased CVD events in patients with NAFLD diagnosed by ultrasonography and have demonstrated that the increased risk for CVD in NAFLD is independent of conventional risk factors and components of the metabolic syndrome^(114–116). These data add to population data that have shown that elevated liver enzymes are also associated with increased risk for CVD^(67,117).

As the treatment of NAFLD involves correcting the same metabolic factors as those involved in CVD, it is prudent that all patients with NAFLD be evaluated for early atherosclerosis. Likewise, patients presenting with the metabolic syndrome or a high Framingham risk score⁽¹¹⁸⁾ should be evaluated for the presence of NAFLD. Children identified with NAFLD or the metabolic syndrome should be strongly counselled to avoid smoking, increase their physical activity and improve their nutrition in order to prevent the development of CVD.

The potential of systems biology

Systems biology is the study of a biological system (cell, tissue, organism) viewed as an integrated and interacting network of genes, proteins and biochemical reactions. This methodology combines computational modelling with experimental biology in order to discover emergent properties that arise from studying a system as a whole; it is these properties that ultimately determine how a system is controlled or regulated. A systems approach begins by constructing a predictive model from which a hypothesis is formed and then tested experimentally by perturbing the system. Experimental techniques are generally the global approaches of genomics, proteomics and metabolomics. Data obtained from these multiple approaches are integrated and compared with the original model, which is refined in an iterative process. In the context of human health it is believed that systems biology is essential to future drug discovery and, indeed, to a future of personalised, predictive and preventative medicine⁽¹¹⁹⁾. In this vision drug targets would be rational and identified through the analysis of normal and disease-perturbed networks, while an individual could have their genome sequenced and in combination with extensive blood analyses would be able to obtain a 'probabilistic future health history'. Although systems biology is in its infancy and this vision still seems far off, global approaches have been applied to NAFLD and have produced data that will be relevant to the future creation of an integrated 'systems' model of NAFLD.

Proteomic technologies are still evolving and the analysis of a complete proteome, in the manner of DNA microarray analysis of complete genomes, has yet to be realised. However, as disease biomarkers and drug targets are most likely to be proteins, proteomics is viewed as central to systems biology and key to predictive medicine⁽¹²⁰⁾. In the context of NAFLD proteomic techniques have been used to analyse adipose⁽¹²¹⁾, liver⁽¹²²⁾ and most recently serum⁽¹²³⁾ samples in patients with NAFLD. Ultimately, it is most likely that a serum diagnostic or prognostic tool for NAFLD would comprise a panel of proteins, and this research highlights the power of systems methodologies for identifying candidate protein biomarkers. Importantly, a 'potential biomarker panel' comprising six proteins has been demonstrated to have greater diagnostic utility than ALT to differentiate between patient groups⁽¹²³⁾. It is also noteworthy that two independent studies^(122,123) have identified lumican, a protein that activates transforming growth factor β and smooth muscle actin, to be elevated in both liver and serum from patients with NASH. These studies have given insight into NAFLD pathogenesis and have identified candidate disease biomarkers worthy of prospective validation.

Conclusion

NAFLD is highly prevalent, with an estimated 20–35% of the UK population affected. Research on the natural history of NAFLD has demonstrated that even simple steatosis cannot be considered benign, as 47% of these patients will progress to NASH within 8–13 years. An estimated 25–50% of patients with NASH will progress to advanced fibrosis and cirrhosis. In real numbers these estimates represent 300 000– 1.8×10^6 cases in the UK, 50% of whom will require a liver transplant to avoid death. It is clear that a diagnosis of NAFLD is associated with increased risk of mortality from liver- and cardiovascular-related events and the British Liver Trust has demonstrated that liver disease is the only major cause of death still increasing yearly in the UK⁽¹²⁴⁾. An additional public health concern is the rising incidence of NAFLD in children who are not exempt from risk of CVD, the need for liver transplants or early death. Part of the challenge in assessing the burden of NAFLD in the population is the lack of a non-invasive screening test for NAFLD.

While NAFLD incidence is strongly linked to insulin resistance and the metabolic syndrome, the development and progression of NAFLD involves a myriad of molecular and cellular events that are influenced by both genetic and environmental factors. In the long term the determination of the critical factors involved in disease progression will identify possible therapeutic targets for treatment of NAFLD and may form the basis of prognostic tests. Proteomic studies are beginning to identify serum and liver proteins found altered in NAFLD. The modelling of NAFLD protein and gene regulatory networks in a systems biology manner has the potential to identify diagnostic, prognostic and therapeutic targets for NAFLD and more research of this type is urgently needed.

Acknowledgements

The author thanks David J. Nolan and Professor Linda M. Morgan for critical review of the manuscript. This review article involved no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The author declares no conflict of interest.

References

- Adler M & Schaffner F (1979) Fatty liver hepatitis and cirrhosis in obese patients. *Am J Med* **67**, 811–816.
- Ludwig J, Viggiano TR, McGill DB *et al.* (1980) Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* **55**, 434–438.
- Day CP & James OF (1998) Steatohepatitis: a tale of two 'hits'? *Gastroenterology* **114**, 842–845.
- Vuppalanchi R & Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. *Hepatology* **49**, 306–317.
- Mofrad P, Contos MJ, Haque M *et al.* (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. *Hepatology* **37**, 1286–1292.
- Schwenzer NF, Springer F, Schraml C *et al.* (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. *J Hepatol* **51**, 433–445.
- Browning JD, Szczepaniak LS, Dobbins R *et al.* (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* **40**, 1387–1395.
- Yoneda M, Yoneda M, Mawatari H *et al.* (2008) Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). *Dig Liver Dis* **40**, 371–378.
- Huwart L, Sempoux C, Vicaut E *et al.* (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* **135**, 32–40.
- Foucher J, Castera L, Bernard PH *et al.* (2006) Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. *Eur J Gastroenterol Hepatol* **18**, 411–412.
- Salameh N, Larrat B, Abarca-Quinones J *et al.* (2009) Early detection of steatohepatitis in fatty rat liver by using MR elastography. *Radiology* **253**, 90–97.
- Poynard T, Ratziu V, Naveau S *et al.* (2005) The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. *Comp Hepatol* **4**, 10.
- Poynard T, Ratziu V, Charlotte F *et al.* (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* **6**, 34.
- Guha IN, Parkes J, Roderick P *et al.* (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* **47**, 455–460.
- Cadranel JF, Rufat P & Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEFL). *Hepatology* **32**, 477–481.
- Gilmore IT, Burroughs A, Murray-Lyon IM *et al.* (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. *Gut* **36**, 437–441.
- Ratziu V, Charlotte F, Heurtier A *et al.* (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* **128**, 1898–1906.
- Wieckowska A, McCullough AJ & Feldstein AE (2007) Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. *Hepatology* **46**, 582–589.
- Hilden M, Christoffersen P, Juhl E *et al.* (1977) Liver histology in a 'normal' population – examinations of 503 consecutive fatal traffic casualties. *Scand J Gastroenterol* **12**, 593–597.
- Wanless IR & Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* **12**, 1106–1110.
- Bellentani S, Saccoccio G, Masutti F *et al.* (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med* **132**, 112–117.
- Dassanayake AS, Kasturiratne A, Rajindrajith S *et al.* (2009) Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. *J Gastroenterol Hepatol* **24**, 1284–1288.
- Garcia-Monzon C, Martin-Perez E, Iacono OL *et al.* (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. *J Hepatol* **33**, 716–724.
- Ratziu V, Giral P, Charlotte F *et al.* (2000) Liver fibrosis in overweight patients. *Gastroenterology* **118**, 1117–1123.
- Dixon JB, Bhathal PS & O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* **121**, 91–100.
- Del Gaudio A, Boschi L, Del Gaudio GA *et al.* (2002) Liver damage in obese patients. *Obes Surg* **12**, 802–804.
- Gholam PM, Flancbaum L, Machan JT *et al.* (2007) Non-alcoholic fatty liver disease in severely obese subjects. *Am J Gastroenterol* **102**, 399–408.
- Gupte P, Amarapurkar D, Agal S *et al.* (2004) Non-alcoholic steatohepatitis in type 2 diabetes mellitus. *J Gastroenterol Hepatol* **19**, 854–858.
- Targher G, Bertolini L, Padovani R *et al.* (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* **30**, 1212–1218.
- Leite NC, Salles GF, Araujo AL *et al.* (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. *Liver Int* **29**, 113–119.
- Weston SR, Leyden W, Murphy R *et al.* (2005) Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. *Hepatology* **41**, 372–379.
- Schwimmer JB, Deutsch R, Kahen T *et al.* (2006) Prevalence of fatty liver in children and adolescents. *Pediatrics* **118**, 1388–1393.
- Chan DF, Li AM, Chu WC *et al.* (2004) Hepatic steatosis in obese Chinese children. *Int J Obes Relat Metab Disord* **28**, 1257–1263.
- Sagi R, Reif S, Neuman G *et al.* (2007) Nonalcoholic fatty liver disease in overweight children and adolescents. *Acta Paediatr* **96**, 1209–1213.
- Sartorio A, Del Col A, Agosti F *et al.* (2007) Predictors of non-alcoholic fatty liver disease in obese children. *Eur J Clin Nutr* **61**, 877–883.
- Damaso AR, do Prado WL, de Piano A *et al.* (2008) Relationship between nonalcoholic fatty liver disease prevalence

- and visceral fat in obese adolescents. *Dig Liver Dis* **40**, 132–139.
37. Lobstein T & Jackson-Leach R (2006) Estimated burden of paediatric obesity and co-morbidities in Europe. Part 2. Numbers of children with indicators of obesity-related disease. *Int J Pediatr Obes* **1**, 33–41.
 38. Schwimmer JB, Pardee PE, Lavine JE *et al.* (2008) Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Circulation* **118**, 277–283.
 39. Pacifico L, Cantisani V, Ricci P *et al.* (2008) Nonalcoholic fatty liver disease and carotid atherosclerosis in children. *Pediatr Res* **63**, 423–427.
 40. Jackson-Leach R & Lobstein T (2006) Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. *Int J Pediatr Obes* **1**, 26–32.
 41. Charlton M (2007) Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. *Am J Gastroenterol* **102**, 409–411.
 42. Musso G, Gambino R & Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). *Prog Lipid Res* **48**, 1–26.
 43. Parekh S & Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. *Gastroenterology* **132**, 2191–2207.
 44. Donnelly KL, Smith CI, Schwarzenberg SJ *et al.* (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* **115**, 1343–1351.
 45. Fabbrini E, Mohammed BS, Magkos F *et al.* (2008) Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. *Gastroenterology* **134**, 424–431.
 46. Guerrero R, Vega GL, Grundy SM *et al.* (2009) Ethnic differences in hepatic steatosis: an insulin resistance paradox? *Hepatology* **49**, 791–801.
 47. Bacon BR, Farahvash MJ, Janney CG *et al.* (1994) Non-alcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* **107**, 1103–1109.
 48. Browning JD & Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* **114**, 147–152.
 49. Anderson N & Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. *Pharmacol Rev* **60**, 311–357.
 50. Tsochatzis EA, Papatheodoridis GV & Archimandritis AJ (2009) Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. *Mediators Inflamm* **2009**, 831670.
 51. Dam-Larsen S, Franzmann M, Andersen IB *et al.* (2004) Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* **53**, 750–755.
 52. Matteoni CA, Younossi ZM, Gramlich T *et al.* (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* **116**, 1413–1419.
 53. Fassio E, Alvarez E, Dominguez N *et al.* (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. *Hepatology* **40**, 820–826.
 54. Ekstedt M, Franzen LE, Mathiesen UL *et al.* (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* **44**, 865–873.
 55. Ratziu V, Bugianesi E, Dixon J *et al.* (2007) Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. *Aliment Pharmacol Ther* **26**, 821–830.
 56. Sanyal AJ, Banas C, Sargeant C *et al.* (2006) Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. *Hepatology* **43**, 682–689.
 57. Feldstein AE, Charatcharoenwittaya P, Treeprasertsuk S *et al.* (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* **58**, 1538–1544.
 58. Angulo P, Keach JC, Batts KP *et al.* (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* **30**, 1356–1362.
 59. Adams LA, Sanderson S, Lindor KD *et al.* (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol* **42**, 132–138.
 60. Rafiq N, Bai C, Fang Y *et al.* (2009) Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol* **7**, 234–238.
 61. Marchesini G, Bugianesi E, Forlani G *et al.* (2003) Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* **37**, 917–923.
 62. Gramlich T, Kleiner DE, McCullough AJ *et al.* (2004) Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. *Hum Pathol* **35**, 196–199.
 63. Argo CK, Northup PG, Al-Osaimi AM *et al.* (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. *J Hepatol* **51**, 371–379.
 64. Crowther MA & Cook DJ (2007) Trials and tribulations of systematic reviews and meta-analyses. *Hematology Am Soc Hematol Educ Program* **2007**, 493–497.
 65. Adams LA, Lymp JF, St Sauver J *et al.* (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* **129**, 113–121.
 66. Ong JP, Pitts A & Younossi ZM (2008) Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol* **49**, 608–612.
 67. Dunn W, Xu R, Wingard DL *et al.* (2008) Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. *Am J Gastroenterol* **103**, 2263–2271.
 68. Ruhl CE & Everhart JE (2009) Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. *Gastroenterology* **136**, 477–485.e411.
 69. Struben VM, Hespeneide EE & Caldwell SH (2000) Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. *Am J Med* **108**, 9–13.
 70. Willner IR, Waters B, Patil SR *et al.* (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. *Am J Gastroenterol* **96**, 2957–2961.
 71. Musso G, Gambino R, De Michieli F *et al.* (2008) Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. *Hepatology* **47**, 1167–1177.
 72. Tokushige K, Hashimoto E, Noto H *et al.* (2009) Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. *J Gastroenterol* **44**, 976–982.
 73. Carulli L, Canedi I, Rondinella S *et al.* (2009) Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. *Dig Liver Dis* **41**, 823–828.
 74. Tokushige K, Takakura M, Tsuchiya-Matsushita N *et al.* (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. *J Hepatol* **46**, 1104–1110.

75. Sazci A, Akpınar G, Aygun C *et al.* (2008) Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. *Dig Dis Sci* **53**, 3218–3224.
76. Romeo S, Kozlitina J, Xing C *et al.* (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* **40**, 1461–1465.
77. Yuan X, Waterworth D, Perry JR *et al.* (2008) Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *Am J Hum Genet* **83**, 520–528.
78. Musso G, Gambino R, De Michieli F *et al.* (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* **37**, 909–916.
79. Toshimitsu K, Matsuura B, Ohkubo I *et al.* (2007) Dietary habits and nutrient intake in non-alcoholic steatohepatitis. *Nutrition* **23**, 46–52.
80. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R *et al.* (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. *J Hepatol* **47**, 711–717.
81. Kim CH, Kallman JB, Bai C *et al.* (2010) Nutritional assessments of patients with non-alcoholic fatty liver disease. *Obes Surg* **20**, 154–160.
82. Spadaro L, Magliocco O, Spampinato D *et al.* (2008) Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. *Dig Liver Dis* **40**, 194–199.
83. Zhu FS, Liu S, Chen XM *et al.* (2008) Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J Gastroenterol* **14**, 6395–6400.
84. Solga S, Alkhuraishe AR, Clark JM *et al.* (2004) Dietary composition and nonalcoholic fatty liver disease. *Dig Dis Sci* **49**, 1578–1583.
85. Kang H, Greenon JK, Omo JT *et al.* (2006) Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. *Am J Gastroenterol* **101**, 2247–2253.
86. Bruce KD, Cagampang FR, Argenton M *et al.* (2009) Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. *Hepatology* **50**, 1796–1808.
87. McCurdy CE, Bishop JM, Williams SM *et al.* (2009) Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. *J Clin Invest* **119**, 323–335.
88. Lirussi F, Azzalini L, Orando S *et al.* (2007) Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database of Systematic Reviews* 2007, issue 1, CD004996. Chichester, West Sussex: John Wiley and Sons, Ltd.
89. Lavine JE (2000) Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. *J Pediatr* **136**, 734–738.
90. Kugelmas M, Hill DB, Vivian B *et al.* (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology* **38**, 413–419.
91. Harrison SA, Torgerson S, Hayashi P *et al.* (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol* **98**, 2485–2490.
92. Chalasani NP, Sanyal AJ, Kowdley KV *et al.* (2009) Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. *Contemp Clin Trials* **30**, 88–96.
93. Lavine JE, Schwimmer JB, Molleston JP *et al.* (2010) Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. *Contemp Clin Trials* **31**, 62–70.
94. Brun P, Castagliuolo I, Di Leo V *et al.* (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* **292**, G518–G525.
95. Wigg AJ, Roberts-Thomson IC, Dymock RB *et al.* (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut* **48**, 206–211.
96. Sabate JM, Jouet P, Harnois F *et al.* (2008) High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. *Obes Surg* **18**, 371–377.
97. Sajjad A, Mottershead M, Syn WK *et al.* (2005) Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* **22**, 291–299.
98. Loguercio C, Federico A, Tuccillo C *et al.* (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. *J Clin Gastroenterol* **39**, 540–543.
99. Li Z, Yang S, Lin H *et al.* (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology* **37**, 343–350.
100. Velayudham A, Dolganiuc A, Ellis M *et al.* (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. *Hepatology* **49**, 989–997.
101. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* **37**, 1595–1607.
102. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* **285**, 2486–2497.
103. Clark JM, Brancati FL & Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* **98**, 960–967.
104. Fan JG, Zhu J, Li XJ *et al.* (2005) Fatty liver and the metabolic syndrome among Shanghai adults. *J Gastroenterol Hepatol* **20**, 1825–1832.
105. Kim HC, Choi SH, Shin HW *et al.* (2005) Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. *World J Gastroenterol* **11**, 5314–5321.
106. Hamaguchi M, Kojima T, Takeda N *et al.* (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* **143**, 722–728.
107. Brea A, Mosquera D, Martin E *et al.* (2005) Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arterioscler Thromb Vasc Biol* **25**, 1045–1050.
108. Targher G, Bertolini L, Padovani R *et al.* (2006) Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. *J Endocrinol Invest* **29**, 55–60.
109. Aygun C, Kocaman O, Sahin T *et al.* (2008) Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. *Dig Dis Sci* **53**, 1352–1357.

110. Fracanzani AL, Valenti L, Bugianesi E *et al.* (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology* **48**, 792–798.
111. Kim HC, Kim DJ & Huh KB (2009) Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. *Atherosclerosis* **204**, 521–525.
112. McKimmie RL, Daniel KR, Carr JJ *et al.* (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. *Am J Gastroenterol* **103**, 3029–3035.
113. Sookoian S & Pirola CJ (2008) Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. *J Hepatol* **49**, 600–607.
114. Targher G, Bertolini L, Rodella S *et al.* (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. *Diabetes Care* **30**, 2119–2121.
115. Hamaguchi M, Kojima T, Takeda N *et al.* (2007) Non-alcoholic fatty liver disease is a novel predictor of cardiovascular disease. *World J Gastroenterol* **13**, 1579–1584.
116. Choi SY, Kim D, Kim HJ *et al.* (2009) The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. *Am J Gastroenterol* **104**, 1953–1960.
117. Schindhelm RK, Dekker JM, Nijpels G *et al.* (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. *Atherosclerosis* **191**, 391–396.
118. Wilson PW, D'Agostino RB, Levy D *et al.* (1998) Prediction of coronary heart disease using risk factor categories. *Circulation* **97**, 1837–1847.
119. Hood L, Heath JR, Phelps ME *et al.* (2004) Systems biology and new technologies enable predictive and preventative medicine. *Science* **306**, 640–643.
120. Weston AD & Hood L (2004) Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. *J Proteome Res* **3**, 179–196.
121. Calvert VS, Collantes R, Elariny H *et al.* (2007) A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. *Hepatology* **46**, 166–172.
122. Charlton M, Viker K, Krishnan A *et al.* (2009) Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. *Hepatology* **49**, 1375–1384.
123. Bell LN, Theodorakis JL, Vuppalanchi R *et al.* (2010) Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. *Hepatology* **51**, 111–120.
124. British Liver Trust (2009) Facts about liver disease. <http://www.britishlivertrust.org.uk/home/media-centre/facts-about-liver-disease.aspx> (accessed June 2009).